Læknablaðið
September 6, 2022
Arny Johannesdottir, Engilbert Sigurðsson
4 citations
The hallucinogen psilocybin is a potential novel treatment for treatment-resistant depression (TRD). Our goal is to review current knowledge on psilocybin and its efficacy in TRD. Literature searches were done on PubMed, Web of Science and Google Scholar, references reviewed in identified articles and other articles found on the website of COMPASS Pathways. Psilocybin treatment consists usually...
BMJ Open
September 1, 2022
Katarina Tabi, Manreet Bhullar, Lenssa Fantu et al.
Introduction: Postpartum depression and anxiety (PPDA) is experienced by up to 20% of families in the first year. The condition impacts not only parents but also their developing child. While mindfulness-based interventions (MBI) have shown to be beneficial for this population, many parents do not have access to treatment or find it challenging to commit or complete the treatment. The COVID-19...
Journal of Affective Disorders
September 1, 2022
Melody J Y Kang, Gustavo Vazquez
BACKGROUND Major Depression is the leading cause of disability worldwide. A cohort of patients do not respond adequately to available antidepressants, leading to treatment-resistant depression (TRD). We evaluated the antidepressant efficacy of an acute intravenous ketamine treatment (0.5 mg/kg) for patients with unipolar TRD, and measured peripheral blood-based biomarkers associated with...
Journal of Affective Disorders
September 1, 2022
Madeline Brendle, Reid Robison, D. Malone
OBJECTIVE The aim of this study was to estimate the cost-effectiveness of esketamine nasal spray relative to intravenous ketamine for patients with treatment-resistant depression (TRD) in the US. METHODS We used a Markov model with a 1-month cycle length, and we estimated quality-adjusted life years (QALYs), costs (2020 USD), and incremental cost-effectiveness ratios (ICER) of esketamine...
International Clinical Psychopharmacology
September 1, 2022
Joseph C.W. Tham, André Do, Jason Fridfinnson et al.
Interest in the use of parenteral ketamine has been increasing over the last 2 decades for the management of treatment-resistant depression (TRD). While intravenous (IV) ketamine has been the most common parenteral route of administration, subcutaneous (SC) and intramuscular options have been described. We developed a clinical treatment protocol for the use of repeated SC racemic ketamine...
BMJ Open
September 1, 2022
Gustavo Vazquez, Gilmar Gutierrez, Joshua D. Rosenblat et al.
6 citations
INTRODUCTION: Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits. The objective of this observational study is to elucidate the association of intranasal (IN) esketamine with beneficial and negative outcomes in the management of...
Psychiatry and Clinical Psychopharmacology
September 1, 2022
Mihriban Heval Özgen, W. van den Brink
In this case report, we present an adult male patient with autism spectrum disorder and a comorbid (treatment-resistant) mood disorder with suicidality. He has been treated with numerous psychopharmaceuticals, most recently risperidone and valproic acid. He has been hospitalized several times and has attempted suicide. He displayed limited social functioning, repetitive behaviors, sensory...
Journal of Affective Disorders
September 1, 2022
Bing Zhang, Wenxian Fu, Yan Guo et al.
BACKGROUND Mindfulness-based cognitive therapy (MBCT) can effectively prevent relapse of major depression, but there is currently insufficient evidence for efficacy against suicidal ideation during depressive episodes. We thus conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing MBCT to treatment as usual (TAU) for suppression of suicidal ideation in...
Nature and Science of Sleep
September 1, 2022
Tian‐He Song, Tingting Wang, Yun‐Yue Zhuang et al.
13 citations
Purpose: Nightmare is common and is also independently implicated in suicide risk among the adolescent population. Adolescents with major depressive disorder (MDD) are at an increased risk of suicide. Therefore, comorbid nightmares may amplify suicide risk among this clinical population. This study aimed to explore the effects of nightmares on suicide risk among adolescents with MDD. Patients...
The Brown University Psychopharmacology Update
September 1, 2022
A medication combining dextromethorphan and bupropion was more efficacious than an active comparator and placebo in reducing depressive symptoms in adults with major depressive disorder, a pair of trials has found. Remission rates with dextromethorphan‐bupropion separated from the comparator and placebo by week 2 of treatment in each study, according to researchers. Results of the Phase 2 trial...